These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8733245)

  • 41. Some immunological investigations on antithrombin III 'Budapest'.
    Lane JL
    Br J Haematol; 1978 Nov; 40(3):459-70. PubMed ID: 107959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antithrombin III deficiency: clinical relevance and replacement therapy.
    Gallus AS
    Dev Biol Stand; 1987; 67():59-66. PubMed ID: 3609485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and characterisation of an antithrombin III mutant (AT Dublin 2) with marginally decreased heparin reactivity.
    Daly M; Ball R; O'Meara A; Hallinan FM
    Thromb Res; 1989 Nov; 56(4):503-13. PubMed ID: 2609289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon].
    Ohsato K; Okamoto K
    Nihon Rinsho; 1993 Jan; 51(1):50-5. PubMed ID: 8381885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma antithrombin activity: a comparative study in normal and diseased animals.
    Raymond SL; Dodds WJ
    Proc Soc Exp Biol Med; 1979 Sep; 161(4):464-7. PubMed ID: 314634
    [No Abstract]   [Full Text] [Related]  

  • 46. [Changing characteristic of blood coagulation factors and their correlation with blood coagulation status in different hepatic diseases].
    Chen J; Duan ZP; Bai L; Zhao J; Ding M; Tong XY; Cong YL
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):206-10. PubMed ID: 22475141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hepatic coagulopathy--principles and therapeutic statements].
    Thaler E; Kleinberger G
    Leber Magen Darm; 1982 Oct; 12(5):193-7. PubMed ID: 7182699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fully automated antithrombin-III assays by synthetic substrate on the Multistat III.
    Bick RL; Wheeler A
    Am J Clin Pathol; 1987 Aug; 88(2):192-7. PubMed ID: 3618551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antithrombin III. Physiologic, physiopathologic and laboratory aspects].
    de Sousa JC; Ferreira R; Carriço F; Nunes V; Geraldes MJ; Parreira F; Ribeiro C
    Rev Port Cardiol; 1991 Sep; 10(9):693-9. PubMed ID: 1747261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation.
    Jourdain M; Carrette O; Tournoys A; Fourrier F; Mizon C; Mangalaboyi J; Goudemand J; Mizon J; Chopin C
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1825-33. PubMed ID: 9412562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pathogenetic mechanism and clinical relevance of acquired anti-thrombin III deficiency in internal medicine (author's transl)].
    Thaler E
    Wien Klin Wochenschr; 1981 Oct; 93(18):563-72. PubMed ID: 7029926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical studies on plasma antithrombin III using an antiserum prepared in our laboratories.
    Cucuianu M; Cristea A; Vonica A; Lascu I
    Med Interne; 1988; 26(3):191-7. PubMed ID: 3187359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Coagulation tests in septic surgical patients].
    Oberhofer D; Kucisec-Tepes N; Skok J; Vucić N; Cala K
    Acta Med Croatica; 2004; 58(5):389-94. PubMed ID: 15756805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parameters of haemostasis during acute venous thrombosis.
    Reiter W; Ehrensberger H; Steinbrückner B; Keller F
    Thromb Haemost; 1995 Aug; 74(2):596-601. PubMed ID: 8584990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Significance of disordered antithrombin III function in disseminated intravascular coagulation and deep venous thrombosis for anticoagulant therapy].
    von Blohn G; Reiter B; Hellstern P; Wenzel E; Köhler M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):426-38. PubMed ID: 6083907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrate.
    Matsuda T; Ogawara M; Miura R; Seki T; Matsumoto T; Teramura Y; Nakamura K
    Thromb Res; 1984 Feb; 33(4):379-88. PubMed ID: 6200949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two automated methods for plasma antithrombin III compared, and the clinical significance of the results.
    Prellwitz W; Schmitt KF; Machner M; Schuster CJ; Weilemann L
    Clin Chem; 1982 Nov; 28(11):2249-53. PubMed ID: 6812990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of immunodepletion of antithrombin III on the response of rabbits to Russell's viper venom-induced activation of factor X.
    Rapaport SI; Toneff T; Rimon A; Warn-Cramer BJ
    Arterioscler Thromb Vasc Biol; 1997 Feb; 17(2):409-16. PubMed ID: 9081698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antithrombin III in patients admitted to intensive care units: a multicenter observational study.
    Messori A; Vacca F; Vaiani M; Trippoli S;
    Crit Care; 2002 Oct; 6(5):447-51. PubMed ID: 12398786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.